What is Theolytics?
Based in England, Theolytics operates as a specialized biotechnology enterprise dedicated to the advancement of oncolytic immunotherapy. The company's core competency lies in its ADENOVO platform, a sophisticated discovery engine that engineers viruses to selectively infect and destroy cancer cells while stimulating a robust immune response. By integrating deep expertise in virology, cancer biology, and immunology, Theolytics is effectively bridging the gap between academic research and clinical application. Their market position is defined by a commitment to precision medicine, aiming to transform the standard of care for patients suffering from solid tumors through targeted, scalable therapeutic solutions.
The company's growth trajectory is supported by a strategic alignment with institutional backers who prioritize long-term scientific impact. As the firm matures, its focus remains on refining its viral delivery mechanisms and expanding its pipeline to address a broader spectrum of oncological challenges, ensuring that its innovative therapies are both efficacious and accessible.
How much funding has Theolytics raised?
Theolytics has raised a total of $6.8M across 1 funding round:
Series A
$6.8M
Series A (2021): $6.8M with participation from TAIHO VENTURES , LLC, Oxford Sciences Enterprises, and Epidarex Capital
Key Investors in Theolytics
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent, billion-pound investment company created in 2015 to found, fund and build transformational businesses via the company's unique partnership with the University of Oxford, the worlds #1 research university.
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs. The firm is led by a diverse team of early-stage investors who act as trusted partners to founders and co-investors.
TAIHO VENTURES , LLC
Taiho Ventures is the corporate venture capital arm of Taiho Pharmaceutical, focusing on strategic investments in early-stage oncology and immunology companies to foster innovation in cancer treatment.
What's next for Theolytics?
With the recent infusion of capital, Theolytics is well-positioned to accelerate its clinical development programs and scale its internal research capabilities. The strategic roadmap likely involves advancing lead candidates through preclinical validation and into early-stage human trials, a critical milestone for any biotech firm in the immunotherapy space. Furthermore, the company is expected to leverage its existing partnerships with biopharmaceutical firms to optimize manufacturing processes and regulatory pathways. As the oncology landscape continues to shift toward personalized, virus-based interventions, Theolytics' ability to execute on its development milestones will be pivotal in determining its long-term commercial viability and potential for future strategic exits or collaborative licensing agreements.
See full Theolytics company page
